-
Amjin, the Pharmaceutical Express, waived its rights to leprosy and tuberculosis products
Time of Update: 2021-01-05
(Pharmaceutical Mission) Jia and Bio-introduced CDK 4/6 inhibitor clinical applications were accepted by the CDE website the latest publicity, Jia and Bio from G1 Therapeutics introduced a class 1 new drug lerociclib tablets in China declared clinical trials, and was accepted.
-
Amjin waived its rights to leprosy and tuberculosis products
Time of Update: 2021-01-01
, Amgen and Australia's non-profit Global Health Drug Development (MDGH) Ltd. announced that they have signed a licensing agreement for AMG 634, a type 4 phosphate type 4 (PDE4) inhibitor that is being studied for the treatment of tuberculosis (TB) and leprosy-related erythema (ENL), the latter of which is caused by complications of leprosy in the skin and throughout the body.
-
Sudden! Gilead applied to disqualify Redsywein and waive the rights.
Time of Update: 2020-08-01
Gilead Sciences said it was confident that the Redsewe regulatory review process would be accelerated even without the status of orphan drugs.
In early March, Gilead Sciences sought fda status for orphan drugs to develop Redsewe as a potential treatment for COVID-19.
-
Experimental COVID-19 vaccine at Imperial College London: Human testing has begun and royalties will be waived
Time of Update: 2020-07-12
The experimental COVID-19 vaccine at Imperial College London has been infusions to the first healthy volunteer at a west London facility In this trial, about 300 people will receive the vaccine an
-
Sanofi waives right to develop two gene therapies in Oxford
Time of Update: 2020-06-17
Oxford Biomedica said on June 8th that Sanofi plans to return the rights to two gene therapy candidates it acquired 11 years ago in partnership with the company It is reported that the two gene therap
-
How can stability studies and expiration dates be waived after oral solid drugs are repackaged into a single dose?
Time of Update: 2017-09-25
It is very convenient for medical institutions and patients to repack oral solid drug products in single dose packaging, which will make the drug have better compliance Therefore, in the past decades,